{"id":955123,"date":"2026-04-27T19:03:12","date_gmt":"2026-04-27T23:03:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/"},"modified":"2026-04-27T19:03:12","modified_gmt":"2026-04-27T23:03:12","slug":"new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/","title":{"rendered":"New Peer\u2011Reviewed Study Reveals Actionable Immune\u2013Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">LA JOLLA, Calif., April  27, 2026  (GLOBE NEWSWIRE) &#8212; MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a study conducted by researchers at the Spanish National Cancer Research Centre (CNIO) has identified macrophage migration inhibitory factor (MIF)\u2013mediated reprogramming of CD74\u2011positive microglia and macrophages as a central vulnerability in brain metastasis. The research, recently published in the peer\u2011reviewed journal \u201c<em>Cancer Research\u201d <\/em>(March 2026), demonstrates pharmacological modulation of this pathway using the brain\u2011penetrant small molecule ibudilast.<\/p>\n<p align=\"justify\">The work, led by Manuel Valiente PhD, head of CNIO Brain Metastasis group, and colleagues at CNIO, shows that tumor\u2011derived MIF alters the functional state of microglia and infiltrating macrophages in the brain, converting them from a potentially protective role into a pro\u2011metastatic one. In multiple experimental models and fresh patient\u2011derived brain metastasis samples, inhibition of the MIF\u2013CD74 signaling axis significantly reduced metastatic progression. Importantly, the investigators also identified secreted MIF as a candidate liquid biopsy biomarker detectable in cerebrospinal fluid, supporting a translational, biomarker\u2011guided clinical strategy.<\/p>\n<p align=\"justify\">The study further demonstrates that ibudilast can effectively block MIF\u2013CD74 signaling, reverse pro\u2011metastatic immune reprogramming, and suppress brain metastasis growth in preclinical systems. In addition, transcriptomic analyses define predictive biomarker signatures associated with treatment response, reinforcing the potential for patient stratification in future clinical studies. The findings suggest translational potential for MN-166 (ibudilast), the company\u2019s leading product, in future therapeutic strategies for brain metastasis within neuro-oncology.<\/p>\n<p align=\"justify\">MediciNova plans to collaborate with Dr. Valiente and CNIO on future clinical research aimed at patients with solid tumors having brain metastases.<\/p>\n<p align=\"justify\">Dr. Valiente commented on the findings, \u201cBrain metastases develop in up to 30% of patients with advanced solid tumors, most commonly arising from lung cancer, breast cancer, melanoma, and colorectal cancer, and remain an area of substantial unmet medical need. Despite recent advances in systemic therapies, patients with brain metastases have historically been excluded from many clinical trials, limiting progress in the development of targeted treatments. By focusing on brain\u2011specific immune\u2013microenvironment interactions rather than tumor\u2011intrinsic alterations alone, the CNIO findings open a new therapeutic avenue that may be applicable across multiple primary tumor types.\u201d<\/p>\n<p align=\"justify\">\u201cBrain metastasis represents one of the most urgent and challenging frontiers in oncology,\u201d said Dr. Kazuko Matsuda, Chief Medical Officer. \u201cThe publication of this work in Cancer Research provides strong mechanistic and translational rationale to pursue biomarker\u2011driven clinical strategies. We hold granted patents covering MN\u2011166 for preventing and minimizing cancer metastasis across multiple solid tumor types, including pancreatic, lung, breast, colorectal and ovarian cancers, as well as melanoma. Our focus is now on advancing future clinical investigations and responsibly translating these insights into studies designed for patients with brain metastases.\u201d<\/p>\n<p align=\"justify\">The full study, <em>\u201cMIF\u2011Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant Across Central Nervous System Disorders,\u201d<\/em> is available online in Cancer Research. (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=32pKqR9EzvUyxx3Umkcv2_pSDuYSkdm6c9upkeq7mAjaDqgVsd6k4M5KxDpi6KCHfTO0dnPgydyaLR8jV4-iXqASD9ZmIp-4vAlCPVMElbis8WOK3JdlugL6F4rVha9QsBPthvUpOpa5feNu0IbbarS7RDnrQFw_oBZmVzyfJqM=\" rel=\"nofollow\" target=\"_blank\">https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-4018<\/a> )<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0MediciNova<\/strong>\n      <\/p>\n<p align=\"justify\">MediciNova, Inc.\u00a0is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles,\u00a0MediciNova\u00a0has numerous programs in clinical development. MediciNova\u2019s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing.\u00a0MediciNova\u00a0has a strong track record of securing investigator-sponsored clinical trials funded through government grants.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166 and MN-001. These forward-looking statements may be preceded by, followed by, or otherwise include the words &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; \u201cconsidering,\u201d \u201cplanning\u201d or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166 and MN-001, and risks of raising sufficient capital when needed to fund\u00a0MediciNova&#8217;s\u00a0operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom\u00a0MediciNova\u00a0relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities,\u00a0MediciNova&#8217;s\u00a0collaborations with third parties, the availability of funds to complete product development plans and\u00a0MediciNova&#8217;s\u00a0ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in\u00a0MediciNova&#8217;s\u00a0filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended\u00a0December 31, 2025\u00a0and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof.\u00a0MediciNova\u00a0disclaims any intent or obligation to revise or update these forward-looking statements.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>INVESTOR CONTACT<\/strong>:<\/p>\n<p>David H. Crean, Ph.D.<br \/>Chief Business Officer<br \/>MediciNova, Inc<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p2WMHCXgx0Zu5aXjDF9IK7g0ks-3JlwqYAxAhpBRtNv2XeVtGdHoJYcIx_6g2r95_BLXgTLzgoCJYBumuDLigS8_RSJ0_6MPk-auZdP2qIOEdKEmgb62AgQOhKgCEf5ydL7NjaeYwnFELbcl295Vx2QqVa6HZhQvacw1mFDSxcbsDh3aW6EEembTLFsNXglFgQR_Jyh3zNjJIqsOsJfJ6R6Mc6Z11rLsEt5wY9ElBDmNgrw384onTcPkQMRqkLXWSu7IyrINC1YmbacxPDs-eA==\" rel=\"nofollow\" target=\"_blank\">info@medicinova.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzgzMCM3NTY4NDg3IzIwMDg1MTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjcyOTlhM2YtMjBmMi00M2M3LTkxYTQtMzA5YzhkZWI4YTZkLTEwMjAwODYtMjAyNi0wNC0yNy1lbg==\/tiny\/MediciNova-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) &#8212; MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a study conducted by researchers at the Spanish National Cancer Research Centre (CNIO) has identified macrophage migration inhibitory factor (MIF)\u2013mediated reprogramming of CD74\u2011positive microglia and macrophages as a central vulnerability in brain metastasis. The research, recently published in the peer\u2011reviewed journal \u201cCancer Research\u201d (March 2026), demonstrates pharmacological modulation of this pathway using the brain\u2011penetrant small molecule ibudilast. The work, led by Manuel Valiente PhD, head of CNIO Brain Metastasis group, and colleagues at CNIO, shows that tumor\u2011derived MIF alters the functional state of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;New Peer\u2011Reviewed Study Reveals Actionable Immune\u2013Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-955123","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Peer\u2011Reviewed Study Reveals Actionable Immune\u2013Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Peer\u2011Reviewed Study Reveals Actionable Immune\u2013Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) &#8212; MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a study conducted by researchers at the Spanish National Cancer Research Centre (CNIO) has identified macrophage migration inhibitory factor (MIF)\u2013mediated reprogramming of CD74\u2011positive microglia and macrophages as a central vulnerability in brain metastasis. The research, recently published in the peer\u2011reviewed journal \u201cCancer Research\u201d (March 2026), demonstrates pharmacological modulation of this pathway using the brain\u2011penetrant small molecule ibudilast. The work, led by Manuel Valiente PhD, head of CNIO Brain Metastasis group, and colleagues at CNIO, shows that tumor\u2011derived MIF alters the functional state of &hellip; Continue reading &quot;New Peer\u2011Reviewed Study Reveals Actionable Immune\u2013Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-27T23:03:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzgzMCM3NTY4NDg3IzIwMDg1MTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"New Peer\u2011Reviewed Study Reveals Actionable Immune\u2013Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation\",\"datePublished\":\"2026-04-27T23:03:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\\\/\"},\"wordCount\":1107,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwNzgzMCM3NTY4NDg3IzIwMDg1MTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\\\/\",\"name\":\"New Peer\u2011Reviewed Study Reveals Actionable Immune\u2013Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwNzgzMCM3NTY4NDg3IzIwMDg1MTM=\",\"datePublished\":\"2026-04-27T23:03:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwNzgzMCM3NTY4NDg3IzIwMDg1MTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwNzgzMCM3NTY4NDg3IzIwMDg1MTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Peer\u2011Reviewed Study Reveals Actionable Immune\u2013Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Peer\u2011Reviewed Study Reveals Actionable Immune\u2013Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/","og_locale":"en_US","og_type":"article","og_title":"New Peer\u2011Reviewed Study Reveals Actionable Immune\u2013Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation - Market Newsdesk","og_description":"LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) &#8212; MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a study conducted by researchers at the Spanish National Cancer Research Centre (CNIO) has identified macrophage migration inhibitory factor (MIF)\u2013mediated reprogramming of CD74\u2011positive microglia and macrophages as a central vulnerability in brain metastasis. The research, recently published in the peer\u2011reviewed journal \u201cCancer Research\u201d (March 2026), demonstrates pharmacological modulation of this pathway using the brain\u2011penetrant small molecule ibudilast. The work, led by Manuel Valiente PhD, head of CNIO Brain Metastasis group, and colleagues at CNIO, shows that tumor\u2011derived MIF alters the functional state of &hellip; Continue reading \"New Peer\u2011Reviewed Study Reveals Actionable Immune\u2013Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-27T23:03:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzgzMCM3NTY4NDg3IzIwMDg1MTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"New Peer\u2011Reviewed Study Reveals Actionable Immune\u2013Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation","datePublished":"2026-04-27T23:03:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/"},"wordCount":1107,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzgzMCM3NTY4NDg3IzIwMDg1MTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/","name":"New Peer\u2011Reviewed Study Reveals Actionable Immune\u2013Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzgzMCM3NTY4NDg3IzIwMDg1MTM=","datePublished":"2026-04-27T23:03:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzgzMCM3NTY4NDg3IzIwMDg1MTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzgzMCM3NTY4NDg3IzIwMDg1MTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"New Peer\u2011Reviewed Study Reveals Actionable Immune\u2013Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=955123"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955123\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=955123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=955123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=955123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}